Histone acetyltransferase inhibitors: An overview in synthesis, structure-activity relationship and molecular mechanism
Acetylation, a key component in post-translational modification regulated by HATs and HDACs, is relevant to many crucial cellular contexts in organisms. Based on crucial pharmacophore patterns and the structure of targeted proteins, HAT inhibitors are designed and modified for higher affinity and be...
Gespeichert in:
Veröffentlicht in: | European journal of medicinal chemistry 2019-09, Vol.178, p.259-286 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 286 |
---|---|
container_issue | |
container_start_page | 259 |
container_title | European journal of medicinal chemistry |
container_volume | 178 |
creator | Huang, Mengyuan Huang, Jiangkun Zheng, Yongcheng Sun, Qiu |
description | Acetylation, a key component in post-translational modification regulated by HATs and HDACs, is relevant to many crucial cellular contexts in organisms. Based on crucial pharmacophore patterns and the structure of targeted proteins, HAT inhibitors are designed and modified for higher affinity and better bioactivity. However, there are still some challenges, such as cell permeability, selectivity, toxicity and synthetic availability, which limit the improvement of HAT inhibitors. So far, only few HAT inhibitors have been approved for commercialization, indicating the urgent need for more successful and effective structure-based drug design and synthetic strategies. Here, we summarized three classes of HAT inhibitors based on their sources and structural scaffolds, emphasizing on their synthetic methods and structure–activity relationships and molecular mechanisms, hoping to facilitate the development and further application of HAT inhibitors.
[Display omitted]
•Three classes of HAT inhibitors were summarized based on their sources and structural scaffolds.•The review focuses on synthetic approaches and modifications with biological results.•Overview of the protein active sites and mechanistic proposals. |
doi_str_mv | 10.1016/j.ejmech.2019.05.078 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2242153572</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0223523419304969</els_id><sourcerecordid>2242153572</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-f79e528a950bf4f96dcc0330498b9e9cbd5263b86a7f70cde045543e28e946b23</originalsourceid><addsrcrecordid>eNp9kE1r3DAQhkVpaDZp_0EpOvZQu_qwZKuHQghNUwjkkpyFLI9ZLba01cgb9t_Xy6Y99jQwPO98PIR85KzmjOuvuxp2M_htLRg3NVM1a7s3ZMNb3VVSqOYt2TAhZKWEbC7JFeKOMaY0Y-_IpeTcKK7NhrzcBywpAnUeynEq2UUcITsEGuI29KGkjN_oTaTpAPkQ4GXtUzzGsgUM-IViyYsvS4bK-RIOoRxphsmVkCJuw566ONA5TeCXyWV6OtjFgPN7cjG6CeHDa70mz3c_nm7vq4fHn79ubx4qL7Uo1dgaUKJzRrF-bEajB--ZlKwxXW_A-H5QQsu-064dW-YHYI1SjQTRgWl0L-Q1-Xyeu8_p9wJY7BzQwzS5CGlBK0QjuJKqPaHNGfU5IWYY7T6H2eWj5cyelNudPSu3J-WWKbsqX2OfXjcs_QzDv9Bfxyvw_QzA-udqMFv0AaKHIWTwxQ4p_H_DH66Il04</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2242153572</pqid></control><display><type>article</type><title>Histone acetyltransferase inhibitors: An overview in synthesis, structure-activity relationship and molecular mechanism</title><source>Elsevier ScienceDirect Journals Complete</source><creator>Huang, Mengyuan ; Huang, Jiangkun ; Zheng, Yongcheng ; Sun, Qiu</creator><creatorcontrib>Huang, Mengyuan ; Huang, Jiangkun ; Zheng, Yongcheng ; Sun, Qiu</creatorcontrib><description>Acetylation, a key component in post-translational modification regulated by HATs and HDACs, is relevant to many crucial cellular contexts in organisms. Based on crucial pharmacophore patterns and the structure of targeted proteins, HAT inhibitors are designed and modified for higher affinity and better bioactivity. However, there are still some challenges, such as cell permeability, selectivity, toxicity and synthetic availability, which limit the improvement of HAT inhibitors. So far, only few HAT inhibitors have been approved for commercialization, indicating the urgent need for more successful and effective structure-based drug design and synthetic strategies. Here, we summarized three classes of HAT inhibitors based on their sources and structural scaffolds, emphasizing on their synthetic methods and structure–activity relationships and molecular mechanisms, hoping to facilitate the development and further application of HAT inhibitors.
[Display omitted]
•Three classes of HAT inhibitors were summarized based on their sources and structural scaffolds.•The review focuses on synthetic approaches and modifications with biological results.•Overview of the protein active sites and mechanistic proposals.</description><identifier>ISSN: 0223-5234</identifier><identifier>EISSN: 1768-3254</identifier><identifier>DOI: 10.1016/j.ejmech.2019.05.078</identifier><identifier>PMID: 31195169</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Drug design ; Drug synthesis ; Epigenetics ; Histone acetyltransferase inhibitors ; Structure-activity relationship</subject><ispartof>European journal of medicinal chemistry, 2019-09, Vol.178, p.259-286</ispartof><rights>2019 Elsevier Masson SAS</rights><rights>Copyright © 2019 Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-f79e528a950bf4f96dcc0330498b9e9cbd5263b86a7f70cde045543e28e946b23</citedby><cites>FETCH-LOGICAL-c362t-f79e528a950bf4f96dcc0330498b9e9cbd5263b86a7f70cde045543e28e946b23</cites><orcidid>0000-0001-5122-2226</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejmech.2019.05.078$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31195169$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Huang, Mengyuan</creatorcontrib><creatorcontrib>Huang, Jiangkun</creatorcontrib><creatorcontrib>Zheng, Yongcheng</creatorcontrib><creatorcontrib>Sun, Qiu</creatorcontrib><title>Histone acetyltransferase inhibitors: An overview in synthesis, structure-activity relationship and molecular mechanism</title><title>European journal of medicinal chemistry</title><addtitle>Eur J Med Chem</addtitle><description>Acetylation, a key component in post-translational modification regulated by HATs and HDACs, is relevant to many crucial cellular contexts in organisms. Based on crucial pharmacophore patterns and the structure of targeted proteins, HAT inhibitors are designed and modified for higher affinity and better bioactivity. However, there are still some challenges, such as cell permeability, selectivity, toxicity and synthetic availability, which limit the improvement of HAT inhibitors. So far, only few HAT inhibitors have been approved for commercialization, indicating the urgent need for more successful and effective structure-based drug design and synthetic strategies. Here, we summarized three classes of HAT inhibitors based on their sources and structural scaffolds, emphasizing on their synthetic methods and structure–activity relationships and molecular mechanisms, hoping to facilitate the development and further application of HAT inhibitors.
[Display omitted]
•Three classes of HAT inhibitors were summarized based on their sources and structural scaffolds.•The review focuses on synthetic approaches and modifications with biological results.•Overview of the protein active sites and mechanistic proposals.</description><subject>Drug design</subject><subject>Drug synthesis</subject><subject>Epigenetics</subject><subject>Histone acetyltransferase inhibitors</subject><subject>Structure-activity relationship</subject><issn>0223-5234</issn><issn>1768-3254</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kE1r3DAQhkVpaDZp_0EpOvZQu_qwZKuHQghNUwjkkpyFLI9ZLba01cgb9t_Xy6Y99jQwPO98PIR85KzmjOuvuxp2M_htLRg3NVM1a7s3ZMNb3VVSqOYt2TAhZKWEbC7JFeKOMaY0Y-_IpeTcKK7NhrzcBywpAnUeynEq2UUcITsEGuI29KGkjN_oTaTpAPkQ4GXtUzzGsgUM-IViyYsvS4bK-RIOoRxphsmVkCJuw566ONA5TeCXyWV6OtjFgPN7cjG6CeHDa70mz3c_nm7vq4fHn79ubx4qL7Uo1dgaUKJzRrF-bEajB--ZlKwxXW_A-H5QQsu-064dW-YHYI1SjQTRgWl0L-Q1-Xyeu8_p9wJY7BzQwzS5CGlBK0QjuJKqPaHNGfU5IWYY7T6H2eWj5cyelNudPSu3J-WWKbsqX2OfXjcs_QzDv9Bfxyvw_QzA-udqMFv0AaKHIWTwxQ4p_H_DH66Il04</recordid><startdate>20190915</startdate><enddate>20190915</enddate><creator>Huang, Mengyuan</creator><creator>Huang, Jiangkun</creator><creator>Zheng, Yongcheng</creator><creator>Sun, Qiu</creator><general>Elsevier Masson SAS</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5122-2226</orcidid></search><sort><creationdate>20190915</creationdate><title>Histone acetyltransferase inhibitors: An overview in synthesis, structure-activity relationship and molecular mechanism</title><author>Huang, Mengyuan ; Huang, Jiangkun ; Zheng, Yongcheng ; Sun, Qiu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-f79e528a950bf4f96dcc0330498b9e9cbd5263b86a7f70cde045543e28e946b23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Drug design</topic><topic>Drug synthesis</topic><topic>Epigenetics</topic><topic>Histone acetyltransferase inhibitors</topic><topic>Structure-activity relationship</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Huang, Mengyuan</creatorcontrib><creatorcontrib>Huang, Jiangkun</creatorcontrib><creatorcontrib>Zheng, Yongcheng</creatorcontrib><creatorcontrib>Sun, Qiu</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huang, Mengyuan</au><au>Huang, Jiangkun</au><au>Zheng, Yongcheng</au><au>Sun, Qiu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Histone acetyltransferase inhibitors: An overview in synthesis, structure-activity relationship and molecular mechanism</atitle><jtitle>European journal of medicinal chemistry</jtitle><addtitle>Eur J Med Chem</addtitle><date>2019-09-15</date><risdate>2019</risdate><volume>178</volume><spage>259</spage><epage>286</epage><pages>259-286</pages><issn>0223-5234</issn><eissn>1768-3254</eissn><abstract>Acetylation, a key component in post-translational modification regulated by HATs and HDACs, is relevant to many crucial cellular contexts in organisms. Based on crucial pharmacophore patterns and the structure of targeted proteins, HAT inhibitors are designed and modified for higher affinity and better bioactivity. However, there are still some challenges, such as cell permeability, selectivity, toxicity and synthetic availability, which limit the improvement of HAT inhibitors. So far, only few HAT inhibitors have been approved for commercialization, indicating the urgent need for more successful and effective structure-based drug design and synthetic strategies. Here, we summarized three classes of HAT inhibitors based on their sources and structural scaffolds, emphasizing on their synthetic methods and structure–activity relationships and molecular mechanisms, hoping to facilitate the development and further application of HAT inhibitors.
[Display omitted]
•Three classes of HAT inhibitors were summarized based on their sources and structural scaffolds.•The review focuses on synthetic approaches and modifications with biological results.•Overview of the protein active sites and mechanistic proposals.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>31195169</pmid><doi>10.1016/j.ejmech.2019.05.078</doi><tpages>28</tpages><orcidid>https://orcid.org/0000-0001-5122-2226</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0223-5234 |
ispartof | European journal of medicinal chemistry, 2019-09, Vol.178, p.259-286 |
issn | 0223-5234 1768-3254 |
language | eng |
recordid | cdi_proquest_miscellaneous_2242153572 |
source | Elsevier ScienceDirect Journals Complete |
subjects | Drug design Drug synthesis Epigenetics Histone acetyltransferase inhibitors Structure-activity relationship |
title | Histone acetyltransferase inhibitors: An overview in synthesis, structure-activity relationship and molecular mechanism |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T03%3A01%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Histone%20acetyltransferase%20inhibitors:%20An%20overview%20in%20synthesis,%20structure-activity%20relationship%20and%20molecular%20mechanism&rft.jtitle=European%20journal%20of%20medicinal%20chemistry&rft.au=Huang,%20Mengyuan&rft.date=2019-09-15&rft.volume=178&rft.spage=259&rft.epage=286&rft.pages=259-286&rft.issn=0223-5234&rft.eissn=1768-3254&rft_id=info:doi/10.1016/j.ejmech.2019.05.078&rft_dat=%3Cproquest_cross%3E2242153572%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2242153572&rft_id=info:pmid/31195169&rft_els_id=S0223523419304969&rfr_iscdi=true |